



**HAL**  
open science

## Normal muscle regeneration requires a tight control of muscle cell fusion by tetraspanins CD9 and CD81

Stéphanie Charrin, Mathilde Latil, Sabrina Soave, Anna Polesskaya, Fabrice Chretien, Claude Boucheix, Eric Rubinstein

### ► To cite this version:

Stéphanie Charrin, Mathilde Latil, Sabrina Soave, Anna Polesskaya, Fabrice Chretien, et al.. Normal muscle regeneration requires a tight control of muscle cell fusion by tetraspanins CD9 and CD81. Nature Communications, 2013, 4, pp.1674. 10.1038/ncomms2675 . inserm-01968759

**HAL Id: inserm-01968759**

**<https://inserm.hal.science/inserm-01968759>**

Submitted on 3 Jan 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ARTICLE

Received 6 Dec 2012 | Accepted 1 Mar 2013 | Published 9 Apr 2013

DOI: 10.1038/ncomms2675

# Normal muscle regeneration requires tight control of muscle cell fusion by tetraspanins CD9 and CD81

Stéphanie Charrin<sup>1,2</sup>, Mathilde Latil<sup>3,4,5</sup>, Sabrina Soave<sup>1,2</sup>, Anna Poleskaya<sup>6,7</sup>, Fabrice Chrétien<sup>3,4,8</sup>, Claude Boucheix<sup>1,2</sup> & Eric Rubinstein<sup>1,2</sup>

Skeletal muscle regeneration after injury follows a remarkable sequence of synchronized events. However, the mechanisms regulating the typical organization of the regenerating muscle at different stages remain largely unknown. Here we show that muscle regeneration in mice lacking either CD9 or CD81 is abnormal and characterized by the formation of discrete giant dystrophic myofibres, which form more quickly in the absence of both tetraspanins. We also show that, in myoblasts, these two tetraspanins associate with the immunoglobulin domain molecule CD9P-1 (EWI-F/FPRP), and that grafting of CD9P-1-depleted myoblasts in regenerating muscles also leads to abnormal regeneration. *In vitro* myotubes lacking CD9P-1 or both CD9 and CD81 fuse with a higher frequency than normal myotubes. Our study unveils a mechanism preventing inappropriate fusion of myotubes that has an important role in the restitution of normal muscle architecture during muscle regeneration.

<sup>1</sup>Inserm, 14 rue Paul Vaillant Couturier, 94807 Villejuif cedex, France. <sup>2</sup>Université Paris-Sud, Institut André Lwoff, 14 rue Paul Vaillant Couturier, 94807 Villejuif cedex, France. <sup>3</sup>Histopathologie Humaine et Modèles Animaux, Département Infection & Epidémiologie; Institut Pasteur, 28 rue du Dr Roux, 75015 Paris, France. <sup>4</sup>Université Versailles Saint Quentin en Yvelines UVSQ, faculté de médecine, 55 Avenue de Paris, 78000 Versailles, France. <sup>5</sup>Université Paris Est Créteil UPEC, 61 Avenue du Général de Gaulle, 94010 Créteil, France. <sup>6</sup>CNRS FRE 3377, CEA Saclay, F-91191 Gif-sur-Yvette, France. <sup>7</sup>Université Paris-Sud, 91191 Gif-sur-Yvette, France. <sup>8</sup>Service d'Anatomie Pathologique et de Médecine légale, Hôpital Raymond Poincaré, Assistance Publique Hôpitaux de Paris AP-HP, 104 Boulevard Raymond Poincaré, 92380 Garches, France. Correspondence and requests for materials should be addressed to S.C. (email: stephanie.charrin@inserm.fr).

The skeletal muscle has a remarkable capacity to regenerate after mechanical or pathological injury. Muscle regeneration occurs in two main phases: the initial degenerative phase is characterized by necrosis of the damaged tissue and activation of an inflammatory response<sup>1</sup>. In the repair phase, the necrotic debris is phagocytosed, and regeneration of myofibres occurs for a large part through the action of satellite cells, skeletal muscle adult stem cells that are located beneath the muscle fibre basal lamina. Primarily quiescent, they can activate on injury and either self-renew or proliferate and further differentiate to become fusion-competent myoblasts<sup>2,3</sup>. Then, according to the severity of the myotrauma, these differentiated myoblasts fuse together to form new multinucleated myofibres or fuse to damaged myofibres. Once fusion of myogenic cells is completed, newly formed myofibres increase in size and under normal conditions, the regenerated muscle is morphologically and functionally indistinguishable from undamaged muscle, strongly suggesting that this process is tightly regulated. However, the regulatory mechanisms that allow the proper reconstitution of muscle architecture remain largely unknown.

A crucial step during the regeneration process is the fusion of myoblasts. Studies in *Drosophila* and in the mouse have yielded considerable molecular information about the proteins mediating the attraction, adhesion and fusion of myoblasts<sup>4,5</sup>. These studies have in particular highlighted the key role of several intracellular proteins, many of them involved in the regulation of cytoskeleton dynamics and have identified a number of surface proteins required for recognition and adhesion of myoblasts but without any intrinsic fusogenic property<sup>4,5</sup>. Some of the molecules which are important for optimal myoblast fusion *in vitro*, including myoferlin<sup>6</sup>, Mannose receptor<sup>7</sup>, Fak<sup>8</sup>, PKC $\theta$  (ref. 9), have been demonstrated to be necessary for normal muscle regeneration in the mouse. In general, their absence yields delayed or abnormal regeneration characterized with properly aligned myofibres, but of reduced diameter, consistent with a decreased number of fusion events.

Besides myoblast fusion, physiological cell–cell fusion in mammals occurs in three circumstances: between the egg and the sperm during fertilization, during the differentiation of macrophages into osteoclasts and giant cells, and for the formation of syncytiotrophoblast during placenta formation<sup>10</sup>. In pathological conditions, cell–cell fusion is induced by a number of viruses, including HIV, and is also a frequent property of tumour cells<sup>11</sup>. Among the molecules that have been shown to have a role in several cell–cell fusion events are the tetraspanins CD9 and CD81. Indeed, the ability of CD9<sup>-/-</sup> oocytes to fuse with sperm is severely impaired<sup>12</sup>. CD81<sup>-/-</sup> mice are hypofertile and CD9<sup>-/-</sup>:CD81<sup>-/-</sup> mice are completely infertile, suggesting a cooperative role of CD9 and CD81 in sperm/egg fusion<sup>13</sup>. However, both CD9 and CD81 negatively regulate HIV-induced cell fusion<sup>14</sup> and macrophage fusion<sup>15</sup>. Altogether, these studies indicate that CD9 and CD81 can act both as positive and negative regulators of cell–cell fusion processes. A major characteristic of tetraspanins is their ability to interact with one another and many other surface proteins, thus building a dynamic network of interactions referred to as the ‘tetraspanin web’. Through this ‘web’, tetraspanins are believed to have a role in membrane compartmentalization<sup>16–18</sup>. This network follows a hierarchical, multi-step assembly process with specific tetraspanins associating in a first step with specific non-tetraspanin partners via direct protein–protein interaction. In a second step, these dimeric complexes can associate with one another via lipid-mediated tetraspanin–tetraspanin interactions. CD9 and CD81 share two common molecular partners, CD9P-1 (also known as EWI-F or FPRP) and EWI-2 (PGRL/IgSF8), members of the Immunoglobulin Superfamily<sup>19–22</sup>. Very few

studies have addressed the function of these two molecules: EWI-2 expression was shown to modulate integrin functions<sup>23,24</sup>, and the ability of CD81 to support *Plasmodium* and hepatitis C virus infection of hepatocytic cells is reduced by CD9P-1 (ref. 25) and a truncated form of EWI-2 (ref. 26), respectively. The role of CD9 and CD81 in myogenesis and muscle regeneration has not been thoroughly investigated. CD9 and CD81 monoclonal antibodies were shown to slightly delay the formation of myotubes by the C2C12 muscle cells, and to trigger apoptotic degeneration of C2C12 myotubes *in vitro*<sup>27</sup>. In addition, ectopic expression of CD9 in a rhabdomyosarcoma cell line increased syncytia formation<sup>27</sup>.


In the present study, we show that the absence of CD9 and CD81 yields abnormal muscle regeneration *in vivo* and a hyperfusion phenotype *in vitro*, due to a large extent to the fusion between myotubes. We also show that these two tetraspanins associate with CD9P-1 in primary myoblasts, and that depletion of this protein by RNA-mediated interference recapitulates the phenotype produced by the absence of CD9 and CD81. Our data reveal a molecular mechanism involving CD9, CD81 and CD9P-1 that prevents the fusion of myotubes and have an essential role in the control of skeletal muscle architecture during muscle regeneration.

## Results

**Upregulation of CD9 and CD81 in regenerating skeletal muscles.** Immunostaining of tibialis anterior (TA) muscle sections from C57BL/6 mice revealed that both tetraspanins are expressed in the muscle (Fig. 1a and Supplementary Fig. S1a). Colabelling with CD31 indicated that CD9 and CD81 are mainly expressed by endothelial cells of endomysial capillaries (Supplementary Fig. S1b). However, myofibres expressed a low level of CD81 (Supplementary Fig. S1b, arrow head) but no detectable CD9. Importantly, using muscle sections from *Tg:Pax7-nGFP* mice (the paired/homeodomain transcription factor *Pax7* is a marker of all satellite cells<sup>28</sup>), we observed that satellite cells expressed both CD9 and CD81 (Supplementary Fig. S1c,d).

To examine the expression of CD9 and CD81 in regenerating muscle, when fusion occurs, we first used the mouse model of notexin-induced acute myoinjury. Four days after injury, the regenerating muscle is characterized by the presence of numerous nascent myofibres, which strongly expressed CD81 as shown by the colabelling with an anti-embryonic myosin antibody (Fig. 1b). CD9 is highly expressed by inflammatory cells recruited in the damaged tissue but remained undetectable on these nascent myofibres (Supplementary Fig. S2a). Both CD81 (Fig. 1c) and CD9 (Supplementary Fig. S2b) were expressed by centrally nucleated myofibres formed 12 days after myoinjury, and their expression levels strongly decreased 4 weeks after injury, a time point characterized by *ad integrum* restitution of the tissue (Supplementary Fig. S2c). We also studied the expression of both tetraspanins in the *Mdx4cv* mouse, a model for Duchenne muscular dystrophy presenting a complete lack of dystrophin<sup>29</sup>. These mice represent a model of chronic muscle regeneration, and are characterized by foci of muscle degeneration/regeneration. This model confirmed the upregulation of CD81 in nascent myofibres and of CD9 at later stages of regeneration (Supplementary Fig. S2d,e).

**Expression of CD9 and CD81 in mouse primary myoblasts.** To further characterize the expression of CD9 and CD81 in myogenic cells, we isolated mouse satellite cells and examined the expression of these two tetraspanins in proliferating and differentiating primary myoblasts. Western blot (Fig. 2a) and flow cytometry (Fig. 2b) showed that both tetraspanins are expressed



**Figure 1 | Expression of CD81 in normal and regenerating adult skeletal muscle.** Cryosections of mouse tibialis anterior (TA) were stained with antibodies to CD81 (red) and Laminin (LM) or embryonic myosin heavy chain (eMyHC) in green, as indicated and analysed by fluorescence microscopy. **(a)** Expression of CD81 in normal muscle; **(b)** 4 days post notexin injection CD81 is upregulated in activated myoblasts as judged by its coexpression with eMyHC. **(c)** Twelve days post notexin injection CD81 is strongly expressed in regenerating fibres (see also Supplementary Figs S1 and S2). For all images the scale bar is 50  $\mu\text{m}$ .


in undifferentiated myoblasts and that their expression levels increase on differentiation concomitantly with differentiation markers such as myosin or troponin (Fig. 2a) to reach a maximal expression level after 2 or 3 days. Confocal microscopy indicated that CD81 (Fig. 2c), and to a lesser extent CD9 (data not shown), colocalized with M-cadherin, which has been shown to have a role in myoblast fusion *in vitro*, at sites of myoblast–myotube or myotube–myotube contacts (Fig. 2c, arrow). In addition, the labelling of CD81 revealed the existence of short and parallel M-cadherin-negative filopodium-like protrusions between myotubes, not yet described to our knowledge (Fig. 2d). CD81 was also localized at the tips of myotubes (Fig. 2e), which make frequent contacts with neighbouring muscle cells (Fig. 2f).

#### CD9 and CD81 negatively regulate muscle cell fusion *in vitro*.

To get further insights into the role of CD9 and CD81 in myoblast fusion, primary myoblasts from mutant and wild-type (WT) mice were analysed for their ability to differentiate in culture. Myoblasts from CD9<sup>-/-</sup> or CD81<sup>-/-</sup> mice generated myotubes that were very similar to those produced by WT myoblasts (data not shown). In contrast, CD9<sup>-/-</sup>::CD81<sup>-/-</sup> myoblasts generated large syncytia that contained more than 30 nuclei (Fig. 2g,h). Several independent isolates of CD9<sup>-/-</sup>::CD81<sup>-/-</sup> myoblasts displayed similar characteristics. Altogether, these data indicate that CD9 and CD81 cooperate to negatively regulate myoblast fusion *in vitro*.

**CD9P-1 and EWI-2 associate with CD9 and CD81 in myoblasts.** The function of tetraspanins is tightly linked to the transmembrane proteins they associate with<sup>16</sup>. We therefore looked for CD9 and CD81 molecular partners that could have a role in myoblast fusion. The major biotin-labelled surface proteins coimmunoprecipitated with CD9 and CD81 comigrated with CD9P-1 and EWI-2, both in proliferating and differentiated myoblasts (Fig. 3a). The coimmunoprecipitation of these two molecules with CD9 and CD81 was confirmed by western blot (Fig. 3b). Reciprocally, both anti-CD9P-1 and anti-EWI-2 antibodies coimmunoprecipitated a fraction of both tetraspanins (Fig. 3b). These data demonstrate that CD9P-1 and EWI-2 associate with CD9 and CD81 at the surface of primary myoblasts. Moreover, as observed with CD9 and CD81, the surface expression level of CD9P-1 increased in myoblasts after 2 days in differentiation medium as determined by flow cytometry (Fig. 3c). In addition, CD9P-1 is weakly expressed on normal muscle (Supplementary Fig. S3a) and during the regeneration process its expression increased in muscle cells where it colocalized with CD81 (Supplementary Fig. S3b).

**CD9P-1 negatively regulates muscle cell fusion *in vitro*.** To investigate the potential role of CD9P-1 and EWI-2 in myoblast fusion, we analysed the differentiation of primary myoblasts after silencing these molecules by RNA-mediated interference (Fig. 3 and Supplementary Fig. S4). CD9P-1-silenced myoblasts formed



**Figure 2 | CD9 and CD81 are expressed in mouse primary myoblasts and regulate fusion *in vitro*.** The expression of CD9 and CD81 was studied in primary cultures of myoblasts induced to undergo differentiation.

(a) By western blot, the expression levels of CD9 and CD81 increase concomitantly with differentiation markers such as myosin or troponin. (b) Flow cytometry analysis shows that CD9 and CD81 are expressed at the surface of undifferentiated myoblasts and that their expression levels increase after induction of differentiation (Ctl: nonspecific fluorescence). (c) Two examples of CD81 localization in differentiated myoblasts as determined by fluorescence confocal microscopy: CD81 (red) partially colocalizes with M-cadherin (M-Cadh, green), in myoblast/myotubes and myotube/myotube contact areas (arrow). (d) CD81 staining reveals short and parallel filopodium-like protrusions between myotubes (higher magnification is shown on the right). (e) CD81 is enriched at myotubes tips, which make frequent contacts with neighbouring muscle cells (arrow) (f). Scale bar in c–f is 25  $\mu$ m. (g) Myoblasts isolated from 8-week-old littermate control and CD9/CD81 null mice were plated at equal density and induced to differentiate. After 3 days of differentiation, cells were fixed and stained with May Grunwald Giemsa. Representative microscopic fields are presented. Scale bar, 200  $\mu$ m. (h) Ten fields of each condition were photographed at  $\times 10$  magnification and nuclei were counted. The histogram shows the mean  $\pm$  s.d. of the percentage of nuclei in cells with different numbers of nuclei and is representative of at least three different experiments (\*\* $P < 0.01$  compared with the control sample, Mann–Whitney test).

large syncytia, which could contain several hundreds of nuclei (Fig. 3d–f). These large syncytia could be observed after 2 or 3 days in differentiation medium, while it took 3 or 4 days for CD9<sup>-/-</sup>::CD81<sup>-/-</sup> myoblasts to generate similar syncytia. Similar results were obtained with two different short interfering RNA (siRNA) oligonucleotides, ruling out possible off-target effects (Supplementary Fig. S4c). The silencing of EW1-2 did not change myoblast fusion (Fig. 3e). Double silencing of CD9 and CD81 also induced the formation of large syncytia (Fig. 3e), confirming the phenotype obtained with myoblasts from CD9<sup>-/-</sup>::CD81<sup>-/-</sup> mice. Of note, CD9P-1 silencing was efficient and did not modify the expression levels of CD9 and CD81 (Supplementary Fig. S4a,b).

#### Lack of CD9P-1 or CD9 and CD81 promotes myotube fusion.


To further understand how the lack of CD9P-1 could induce the formation of large syncytia, we analysed by time-lapse videomicroscopy the behaviour of cells treated with a control siRNA or a siRNA targeting CD9P-1 during the differentiation process (Fig. 4 and Supplementary Movies 1 and 2). The first hours of differentiation are characterized by elongation and migration of myoblasts, which were similar in both conditions. After 24 h, only few cells had fused. At this stage, there was a twofold increase in the number of multinucleated cells after depletion of CD9P-1 ( $9 \pm 0.4\%$  versus  $4 \pm 1.4\%$ ; about 1,000 cells examined). Moreover, 1.4% of CD9P-1-depleted cells had already 5–10 nuclei (versus 0 for control cells). Thus, the absence of CD9P-1 leads to an increase of the fusion of myoblasts.

The myotubes formed in both conditions were very mobile and their tips highly dynamic, allowing frequent contacts between myotubes. Despite these contacts, control myotubes in particular the large ones rarely fused with one another. In contrast, after depletion of CD9P-1 many large myotubes fused with one another with a high efficiency: most myotubes fused at least once with other myotubes during the course of the recording, and many myotubes underwent several successive fusions with neighbouring myotubes leading to the formation of giant branched syncytia (Fig. 4, 48–65 h and Supplementary Movies 1 and 2). Similarly, we observed that the branched structures formed by CD9<sup>-/-</sup>::CD81<sup>-/-</sup> myoblasts also resulted from the fusion of myotubes (Supplementary Movie 3).

From these data we conclude that the increased size of the syncytia observed in the absence of CD9P-1 or both CD9 and CD81 is due not only to an increase in the rate of myoblast fusion, but also and mainly to a dramatic increase in the number of myotubes fusing with each other.

#### Dystrophic muscle regeneration in the absence of CD9 or CD81.

Finally, we investigated whether the hyperfusion phenotype observed in the absence of CD9 and CD81 *in vitro* was associated with a defect of regeneration (Fig. 5). Uninjured tibialis anterior muscles of CD9<sup>-/-</sup>, CD81<sup>-/-</sup> and CD9<sup>-/-</sup>::CD81<sup>-/-</sup> mice were morphologically normal (Fig. 5a–d). Four days after notexin injury, WT regenerating muscles displayed myoblasts/nascent myofibres containing 2 or 3 centrally located nuclei and an eosinophilic cytoplasm. At this time point, there was no major difference in CD9<sup>-/-</sup> or CD81<sup>-/-</sup> mice compared with the control mice, except for the presence of some nascent myofibres containing more than three nuclei (Fig. 5f,g). Twelve days after notexin injection, control muscles contained numerous centronucleated myofibres with a diameter of  $34.5 \pm 9.11 \mu$ m. The regenerating muscles of CD9<sup>-/-</sup> or CD81<sup>-/-</sup> mice showed several abnormalities: the myofibres had an increased diameter ( $57.5 \pm 11.2$  and  $69.4 \pm 12 \mu$ m, respectively) associated with a greater size distribution (15–98  $\mu$ m in mutant mice versus




**Figure 3 | CD9P-1 associates with CD9 and CD81 and negatively regulates myoblast fusion.** (a) After biotinylation of cell surface proteins, proliferating myoblasts (D0) or after 3 days in differentiation medium (D3) were lysed with Brij97 and immunoprecipitations (IP) were performed as indicated on the top of each lane. The proteins in the immunoprecipitates were revealed using IRdye800-conjugated streptavidin. Bands corresponding to CD9P-1, EWI-2, CD81 and CD9 are indicated on the right. Note that the integrin  $\beta 1$  subunit comigrates with CD9P-1. In b, the composition of the different IPs was analysed by Western blot. As a control, an anti-integrin  $\alpha 5$  (Int.  $\alpha 5$ ) antibody did not coimmunoprecipitate CD9, CD81 or CD9P-1. TL, total cell lysate. Asterisk (\*) indicates a nonspecific band. (c) Flow cytometry analysis shows that CD9P-1 is expressed at the surface of undifferentiated myoblasts and its expression increases after 2 days in differentiation conditions (Ctl: nonspecific fluorescence). (d) Primary myoblasts were transfected with a siRNA oligonucleotide targeting CD9P-1 (siCD9P-1) or with a control siRNA (siCont); contrast phase: representative microscopic fields after 48 h of differentiation. Scale bar, 50  $\mu$ m. (e) Primary myoblasts were left untransfected (NT) or were transfected with a siRNA oligonucleotide targeting CD9P-1 (siCD9P-1), EWI-2 (siEWI-2), both CD9 and CD81 (siCD9+CD81) or with a control siRNA (siCont). After 48 h of differentiation, cells were fixed and ten fields of each condition were photographed at  $\times 10$  magnification and nuclei were counted. The histogram shows the mean  $\pm$  s.d. of the percentage of nuclei in cells with different numbers of nuclei and is representative of at least three different experiments.  $\emptyset$ : not observed. (f) Number of nuclei in control or CD9P-1-silenced myotubes containing more than 30 nuclei. Note that this quantification underestimates the number of nuclei in the largest syncytia because only the part of the syncytium observed in each field is taken into consideration (\*\* $P < 0.01$ , \* $P < 0.05$  as compared with the control, Mann-Whitney test).

18–54  $\mu$ m in control mice). In addition, many of the myofibres were dystrophic (Fig. 5i–k): they were hyperchromatic, eosinophilic (an hallmark of high cytoplasmic protein content) and contained numerous elongated nuclei. Both the cytoplasmic compartment and nuclei formed whorls frequently separated by vacuoles. Importantly, the regeneration defect is accelerated in CD9<sup>-/-</sup>::CD81<sup>-/-</sup> mice. Indeed, the regenerating muscles of these mice displayed, 4 days after notexin injection, numerous hyperchromatic multinucleated myoblasts, some of which containing centrally located chains of nuclei (Fig. 5h). Moreover, at this stage, we already observed some giant dystrophic myofibres (Fig. 5h), similar to those observed only 12 days post injury in single knockout mice. Finally, the muscles of mutant animals failed to restore a normal architecture 1 month after notexin injection, in contrast to the muscles of control animals. In particular, many dystrophic structures were still observed at this stage (Fig. 5n–p). Analysis of longitudinal sections confirmed the formation of abnormal myofibres during the regeneration process in the

absence of CD9 and/or CD81. Twelve days post injury, the regenerating fibres of control mice had a diameter  $< 60 \mu$ m and a single chain of centrally located nuclei (Fig. 6a,b). Mutant mice showed regenerating myofibres of diameters  $> 100 \mu$ m, some of which containing several parallel chains of nuclei (Fig. 6c–f). In addition, some of these large myofibres were in the continuity of two myofibres of normal size (Fig. 6d–f (arrow)). These morphological features are compatible with the fusion of two myofibres.

To further characterize the dystrophic structures of CD9<sup>-/-</sup>::CD81<sup>-/-</sup> animals, transverse sections were stained for laminin, actin bundles (using phalloidin) or  $\alpha$ -actinin (a z-disc component<sup>30</sup>; Fig. 7). In WT sections, actin staining displayed a granular aspect, consistent with a transversal sectioning of parallel myofibrils (Fig. 7a). In many dystrophic structures of mutant animals, this granular aspect coexisted with a staining of actin bundles in different orientations (Fig. 7b,c). The occurrence in some dystrophic structures of areas displaying a punctuated



**Figure 4 | Lack of CD9P-1 promotes the fusion of myotubes.** Primary myoblasts were transfected with a control siRNA (siCont) or with a siRNA oligonucleotide targeting CD9P-1 (siCD9P-1) and recorded by time-lapse videomicroscopy. Images were acquired at 10-min intervals. The arrow shows a contact between two WT myotubes that is not followed by fusion and the arrowheads show the fusion between CD9P-1-depleted myotubes. Scale bars, 100  $\mu$ m. See also Supplementary Movies 1 and 2.


$\alpha$ -actinin staining pattern, adjacent to regions showing a striated staining pattern, was also coherent with the presence in the same myofibres of myofibrils in different orientations (Fig. 7e,f and Supplementary Fig. S5). Moreover, the  $\alpha$ -actinin labelling revealed another feature of the dystrophic myofibres. While in WT transversal muscle sections, due to the alignment of z-discs, the  $\alpha$ -actinin labelling in each individual myofibre is in the same plane, in dystrophic myofibres of mutant animals the uneven z-planes staining of  $\alpha$ -actinin revealed contiguous areas in which z-discs were not aligned (Fig. 7b,e,f). This misalignment of z-discs was particularly apparent for ring-like structures, in which the periphery and the central part of the structure have misaligned myofibrils (Fig. 7f). Some of these structures contained discontinuous internal laminin and compressed nuclei at the junction of the two parts of the structure (Fig. 7c and Supplementary Fig. S5).

**Absence of CD9P-1 in myoblast alters muscle regeneration.** Finally, to determine whether the lack of CD9P-1 also affects regeneration *in vivo*, we grafted control and CD9P-1-silenced

myoblasts into regenerating TA muscles 24 h after a cardiotoxin injury. As early as 4 days post-grafting, the engraftment of CD9P-1-silenced cells, in contrast to control cells, yielded the formation of the typical giant dystrophic myofibres (Fig. 8) observed in the absence of CD9 or CD81. These aberrant structures were also characterized by a disorganization of the myofibrils as judged by the staining pattern of actin and  $\alpha$ -actinin (Fig. 8).

## Discussion

The skeletal muscle has a remarkable ability to respond to injury by activating a well-orchestrated regenerative response that perfectly restores tissue architecture. The mechanisms underlying the *ad integrum* restitution of the muscle have remained largely unknown. Our study suggests that the adequate repair of the muscle relies at least in part on a tight control of the fusion ability of myogenic cells, especially myofibres. This conclusion is based on the demonstration that in the absence of the tetraspanins CD9 and CD81, or after silencing their major molecular partner CD9P-1; (a) muscle regeneration is abnormal and characterized by a loss of the normal architecture, and (b) myotubes fuse one to



**Figure 5 | Muscle regeneration is abnormal in the absence of CD9 or CD81.** Representative cross-sections of control, CD9<sup>-/-</sup>, CD81<sup>-/-</sup> and CD9<sup>-/-</sup>;CD81<sup>-/-</sup> TA stained with haematoxylin and eosin. (a-d) Uninjured; (e-h) 4 days after notexin injection; (i-l) 12 days after notexin injection; (m-p) 1 month after notexin injection. Examples of normal or dystrophic structures are shown at higher magnification in inset. Scale bars, 100 μm; insets, 50 μm.


another with a high frequency *in vitro*, in contrast to control myotubes.

The fusion between myotubes *in vitro* has previously been reported<sup>31,32</sup>, and it has also been suggested that some myofibres could fuse one to another *in vivo* during regeneration<sup>33</sup>. In our conditions, the fusion of two normal myotubes *in vitro* was a rare event as shown by videomicroscopy. In contrast, in the absence of both CD9 and CD81, or in the absence of CD9P-1, most myotubes fused to other myotubes, leading to the formation of large branched syncytia *in vitro*. These data strongly suggest the existence of a mechanism preventing the fusion between myotubes, in which these three molecules have a central role. Several data indicate that the abnormal muscle regeneration observed in the absence of CD9 and CD81, or CD9P-1 is at least in part a consequence of dysregulated fusion. First, 4 days after notexin injection, the regenerating muscles of CD9/CD81 null mice display myoblasts with more than three nuclei, in contrast to WT animals. Second, the giant dystrophic structures observed in the absence of these molecules display a number of features suggesting that they result from the abnormal fusion of myofibres. These features include the existence of myofibres with two or three parallel chains of nuclei, apparent merging of

two myofibres, and the presence of bundles of myofibrils that are either misaligned or are in different orientations. We therefore conclude that CD9, CD81 and CD9P-1 act as negative regulators of myofibre fusion during the regeneration process, thereby having a major role in maintaining the muscular architecture during this process.

Importantly, the dystrophic structures formed during the regeneration of CD9 and CD81 null mice show similarities with abnormal myofibres observed in several myopathies. In particular, the presence in myofibres of actin bundles having different orientations is reminiscent of ring fibres classically associated with late stages of myotonic dystrophies<sup>34,35</sup>. It would be interesting to determine whether these abnormal fibres are the result of a defective control of fusion, and to evaluate the function of CD9, CD81 and CD9P-1 in these pathologies.

Based on the commonly proposed function of tetraspanins, we hypothesize that CD9 and CD81 might negatively regulate the function of one or several players of myotube fusion through membrane compartmentalization. Our results point to the key role of one of their partners, CD9P-1. The fact that the hyperfusion phenotype is obtained faster on CD9P-1 silencing than in the absence of CD9 and CD81 is consistent with the idea



**Figure 6 | Longitudinal sections of regenerating muscles from normal and CD9/CD81 mutant mice.** Haematoxylin and eosin staining of 1  $\mu\text{m}$  resin-embedded longitudinal sections of regenerating muscles 12 days after notexin injection. (a,b) Normal control mice showing classical features of regenerating fibres forming fibres with centrally located nuclei. (c-f) Mutant mice showing large regenerating myofibres, many of which containing several parallel chains of nuclei. Arrows indicate the apparent merging of two myofibres. (c) CD81<sup>-/-</sup> mutant, (d) CD9<sup>-/-</sup>::CD81<sup>-/-</sup> mutant, (e,f) CD9<sup>-/-</sup> mutant. Scale bar, 50  $\mu\text{m}$ .

that CD9 and CD81 may function through the regulation of CD9P-1. The function of CD9P-1 is unknown. It was originally described as a protein copurifying with a prostaglandin F2 $\alpha$ -binding protein, and was subsequently suggested to negatively modulate the binding of PGF2 $\alpha$  on its receptor<sup>36,37</sup>. Interestingly, PGF2 $\alpha$  was shown to stimulate myoblast fusion<sup>38</sup>. However, the increased fusion observed after CD9P-1 silencing is not due to an increased stimulation of the PGF2 $\alpha$  receptor as it is not blocked by inhibition of this receptor (Supplementary Fig. S4d). The mTOR pathway was also shown to be required for secondary myoblast/myotube fusion<sup>39</sup>, but was found to be dispensable for the increased myotube/myotube fusion observed on CD9P-1 silencing (Supplementary Fig. S4e,f). The recent demonstration that CD9P-1, CD9 and CD81 associate with the  $\gamma$ -secretase complex<sup>40</sup> raised the hypothesis that these molecules could increase the fusion by regulating the Notch pathway, which has a key role in the balance between self-renewal of satellite cells and their engagement towards differentiation<sup>41</sup>. Indeed,  $\gamma$ -secretase-mediated cleavage of Notch is an essential step of this pathway<sup>42</sup>. Inhibition of Notch activity by overexpression of Numb, an antagonist of Notch, or using  $\gamma$ -secretase inhibitor DAPT, was shown to enhance the size of myotubes *in vitro* by increasing the recruitment of fusing-competent cells<sup>43</sup>. However, the effect of depletion of CD9P-1 is unlikely to be a consequence of altered Notch signalling as we observed no significant change in the expression of Notch targets, *hes-1* and *hey-1* (Supplementary Fig. S4g), that have been demonstrated to be under the control of Notch in adult myogenic progenitors<sup>44</sup>. The precise mechanisms through which CD9P-1 regulates muscle cells fusion will require further investigations.


The fusion of myoblasts isolated from CD9 or CD81 null mice was normal while that of CD9/CD81 null mice was greatly enhanced. *In vivo*, the deletion of only one of these two tetraspanins was sufficient to alter the regeneration process. However the absence of both molecules accelerated the appearance of dystrophic structures. Altogether, these results indicate that while CD9 and CD81 have a similar role during muscle regeneration, they cannot completely compensate for each other during this process. Similar conclusions were reached in other fusion processes: the fertility of CD81 null mice is reduced,

but not as much as that of CD9 null mice, and the absence of CD81 in addition to that of CD9 completely abolishes the ability of the egg to fuse with sperm<sup>12,13</sup>. In addition, in the absence of either CD9 or CD81 alveolar macrophages had an increased ability to form multinuclear giant cells both *in vitro* and *in vivo*, in response to *Propionibacterium acnes*. However, mice spontaneously developed multinuclear giant cells in the lung only in the absence of both tetraspanins<sup>15</sup>. The similar roles of CD9 and CD81 in several fusion processes are probably linked to their relatively high degree of identity as compared with other tetraspanins, and to their ability to directly associate with the same partner proteins, including CD9P-1 and EWI-2, another protein of unknown function related to CD9P-1 (refs 19–22). It is not known why CD9 and CD81 are either positive or negative regulators of cell fusion depending on the cellular system. This may depend on the nature of the molecules they associate with, or the balance of different associated molecules. In this regard, the expression of EWI-2 is strongly diminished in CD9 null oocytes<sup>45</sup>, which led to the suggestion that the reduced ability of the eggs to fuse in the absence of CD9 could be due to the decreased expression of this molecule. However, a recent report showed that mice lacking EWI-2 had a normal fertility<sup>46</sup>. Of note, EWI-2, in contrast to CD9P-1, did not influence myoblast fusion in this study.

In conclusion, this study unveils a mechanism that prevents inappropriate fusion of myogenic cells and that is essential for adequate muscle regeneration. It shows for the first time that a role of tetraspanins in a cell–cell fusion process can be recapitulated by one of their associated proteins, and unravels new role for CD9P-1/EWI-F. Further work should be done to determine how these molecules regulate the fusion process, and their contribution in various pathological muscular conditions where dystrophic myofibres are observed, especially in myotonic dystrophy.

## Methods

**Ethical.** All mice received food and water *ad libitum*. Before manipulations mice were anaesthetized with an intraperitoneal injection of 0.1 ml per 10 g mouse body weight of a solution containing 1 mg ml<sup>-1</sup> xylazine (Rompun 2%, Bayer, Leverkusen, Germany) and 10 mg ml<sup>-1</sup> ketamine (Imalgène 1000, Merial, Lyon, France) per mouse. This study was conducted in accordance with the European Communities Council (Directive 2010/63/EU) (ref. 47).




**Figure 7 | Actin and  $\alpha$ -actinin organizations in regenerating myofibres.** Fluorescence confocal microscopy analyses of cryosections of TA from control and mutants mice 12 days after notexin injection. (**a–c**) Three-dimensional projections from 1.3  $\mu\text{m}$  z-stack of sections stained with 4',6-diamidino-2-phenylindole (DAPI; blue), an anti-laminin antibody (red) and phalloidin (grey) to reveal actin (**a**: control mice; **b**:  $\text{CD9}^{-/-}::\text{CD81}^{-/-}$ ; **c**:  $\text{CD9}^{-/-}$ ). (**d–f**) Three-dimensional projections from successive 1.3  $\mu\text{m}$  z-stack of cryosections stained with DAPI (blue), an anti-laminin antibody (red) and an anti- $\alpha$ -actinin antibody (grey) (**d**: control mice; **e**:  $\text{CD9}^{-/-}::\text{CD81}^{-/-}$ ; **f**:  $\text{CD81}^{-/-}$ ). Note that the same sections are analysed in **a** and **d**, as well as in **b** and **e**. For all images the scale bar is 20  $\mu\text{m}$ . See also Supplementary Fig. S4.

**Mice strains.** All experiments were conducted with 6- to 8-week-old animals. WT C57BL/6 mice used for tetraspanins expression analysis were obtained from Janvier (Le Genest Saint Isle, France). *Tg:Pax7-nGFP* mice were described previously<sup>28</sup>. The expression of nGFP corresponds with that of the endogenous *Pax7* gene in the embryo and in the adult and labels all satellite cells. C57BL/6  $\text{CD81}^{-/-}$  and  $\text{CD9}^{-/-}$  were obtained from the crossing of heterozygotes. The animals were genotyped as previously described<sup>12,48</sup>.

Double knockout  $\text{CD9}^{-/-}::\text{CD81}^{-/-}$  mice were obtained by successive crossings of the two strains.

**Muscle injury and tissue preparation.** For muscle injury, 10  $\mu\text{l}$  of the phospholipase A2 notexin (12.5  $\mu\text{M}$  in PBS, Latoxan, France) were injected intramuscularly with an Hamilton precision syringe into the TA muscle. At various times after



**Figure 8 | Muscle regeneration after grafting of control or CD9P-1-silenced myoblasts.** Primary myoblasts were transfected with a siRNA oligonucleotide targeting CD9P-1 (siCD9P-1) or with a control siRNA (siCont) and were grafted into regenerating TA 24 h after a cardiotoxin injury. (a–d) Representative haematoxylin/eosin-stained cross-sections of muscles grafted with control myoblasts (a,b) or CD9P-1-silenced myoblasts (c,d) 4 days after grafting. Scale bar, 50  $\mu\text{m}$ . (e) Three-dimensional projections from 1.3  $\mu\text{m}$  confocal microscopy z-stack of cryosections of TA grafted with CD9P-1-silenced myoblasts stained with 4',6-diamidino-2-phenylindole (DAPI; blue), an anti-laminin antibody (red) and phalloidin to reveal actin (grey). (f) Three-dimensional projections from 1.3  $\mu\text{m}$  successive z-stacks of the same muscle cryosection as in e stained with DAPI (blue), an anti-laminin antibody (red) and an anti- $\alpha$ -actinin antibody (grey). Scale bar, 20  $\mu\text{m}$ . (\* indicates a normal myoblast). The results are representative of two different silencing experiments, where five mice were grafted with myoblasts treated with a control siRNA in the left TA and with CD9P-1-silenced myoblasts in the right TA.

injection (4 days, 12 days and 1 month), muscles were dissected and either snap frozen in nitrogen-chilled isopentane and kept at  $-80^\circ\text{C}$ , or fixed using buffered 4% paraformaldehyde for 2 h before cryopreservation in 40% sucrose overnight at  $4^\circ\text{C}$  (for *Tg:Pax7-nGFP* mice), or embedded with the Leica Histo-resin Embedding kit (Leica Microsystems, Germany) (for analyses in longitudinal section) before sectioning (7, 14 or 1  $\mu\text{m}$ , respectively), haematoxylin and eosin stainings and immunohistochemistry. Microscopic examination was performed with a Nikon 50i microscope with a numeric acquisition system and Nikon NisD software.

**Grafting experiment.** Primary myoblasts were transfected with a control siRNA or a siRNA targeting CD9P-1 (see RNA interference section) 1 day after their isolation. Cells (80,000) were grafted by direct intramuscular injection into cardiotoxin-injured regenerating TA (24 h post injury) of C57Bl/6 mice.

**Primary muscle cell culture.** Primary myoblasts were isolated from TA muscles of 6-week-old mice by enzymatic digestion as described<sup>49</sup>. All functional experiments were performed with cells isolated from three animals for each genotype. Myoblasts were grown in growth media (Ham's F10 (PAA), 20% fetal bovine serum, 5 ng ml<sup>-1</sup> bFGF (Invitrogen), 100 U ml<sup>-1</sup> penicillin G, 100  $\mu\text{g}$  ml<sup>-1</sup> streptomycin and neomycin 100  $\mu\text{g}$  ml<sup>-1</sup>) on collagen-coated dishes. For differentiation, myoblasts were plated at  $10^5$  per well of collagen-coated 24-well dishes and differentiation was induced by switching the growth medium to differentiation medium (DM: DMEM containing 5% horse serum) for different times, the day of the induction is referenced as D0.

**RNA interference.** RNA interference was performed using Lipofectamine RNAi-MAX reagent (Invitrogen) according to the manufacturer recommendations. The cells were transfected 1 day before and 1 day after the induction of differentiation.

All siRNA including the siRNA oligonucleotide control were synthesized by Eurogentec except siCD9P-1\_2, which is a stealth siRNA from Invitrogen. They targeted

CD81 (5'-GCACCAATATGCATCAAATA-3'),  
 CD9 (5'-GAGCATCTTCGAGCAAGAG-3'),  
 CD9P-1 (siCD9P-1\_1: 5'-CATTGAGATGACTTGCAA-3' and siCD9P-1\_2: 5'-GACACATTCAATTTCCGGATCCAAA-3')  
 or EW1-2 (5'-GTTCTCCTATGCTGTCTTT-3').

**Inhibitor treatments.** In experiments using inhibitors, vehicle (DMSO: dimethylsulphoxide diluted in DM), AL8810 ( $10^{-6}\text{M}$ ) (Cayman), or rapamycin (50 nM) (R&D Systems) were added to DM at D0 and replenished at 24 h for a total treatment of 48 h. When necessary, the cells were fixed and stained with May Grunwald Giemsa and counted. Ten fields of each cell types were photographed at  $\times 10$  magnification and the distribution of myotubes according to their nuclei content (1–4; 5–10; 10–30 and more than 30) was determined.

**Time-lapse imaging.** Time-lapse Videomicroscopy was performed using an Axiovert 200 inverted microscope (Zeiss, Oberkochen, Germany) equipped with a temperature and CO<sub>2</sub>-controlled chamber. Images were acquired at 10 or 15 min intervals with a Coolsnap HQ camera (Roper Scientific) driven by the Metamorph software (Roper Scientific). Movies were exported and converted into a AVI file displaying images at the speed of 15 frames s<sup>-1</sup>.

**Quantitative reverse transcription-PCR.** For quantitative reverse transcription-PCR, total RNA fraction was isolated from myoblasts transfected with siRNA control or targeting CD9P-1 after 48 h in DM using Trizol according to the manufacturer's instructions. Subsequently, cDNA was synthesized from 1  $\mu\text{g}$  of

total RNA from each sample using 200 U of SuperScript III Reverse Transcriptase (Invitrogen) primed with random hexamer (Promega). Quantitative real-time polymerase chain reactions (QPCRs) were then carried out in a final volume of 25  $\mu$ l containing 2  $\times$  Brilliant II SYBR Green QPCR Master Mix from Agilent, 0.4  $\mu$ M each forward and reverse primers and 62.5  $\mu$ g of cDNA. Quantification was performed with the Mx3005P QPCR Systems and MxPro software from Agilent. For each cDNA sample, triplicates were analysed and data normalized to cyclofilin A expression according to the  $\Delta C_t$  method. The primers used for the study are as follows:

Hes-1 Forward primer (5'-3') GAAAGATAGCTCCCGGCATT, reverse primer (5'-3') GTCACCTCGTTCATGCACTC;

Hey-1 Forward primer (5'-3') GCGCGGACGAGAATGGAAA, reverse primer (5'-3') TCAGGTGATCCACAGTCATCTG;

Cyclofilin A Forward primer (5'-3') GTCACCCACCGTGTCTT, reverse primer (5'-3') ACAAGGTCCCAAAGACAGCAG.

**Antibodies.** The anti-mouse CD9 (4.1F12) and CD81 monoclonal antibodies (MT81) have been described elsewhere<sup>50</sup>. Two antibodies for CD9P-1 were used: monoclonal antibody 8G1 described in<sup>25</sup> for immunoprecipitation and a sheep polyclonal anti-mouse FPRP from R&D Systems for western blot, FACS analysis and immunohistochemistry (IHC) (10  $\mu$ g ml<sup>-1</sup>). A goat polyclonal anti-mEWI-2 (10  $\mu$ g ml<sup>-1</sup>) was purchased from R&D Systems and an anti-mouse  $\alpha 5$  integrin mAb MFR5 (10  $\mu$ g ml<sup>-1</sup>) from BD Pharmingen (Le Pont de Claix, France). The anti-M-cadherin mAb (12G4, 1/20) is from Calbiochem. The monoclonal antibody to Troponin T (JLT-12, 1/500), Myosin Heavy Chain (My-32, 1/1,000),  $\alpha$ -actinin (EA-53, 1/5,000) and  $\beta$ -tubulin (tub 2.1, 1/3,000) and the rabbit polyclonal anti-mouse Laminin-2 are from Sigma-Aldrich (Saint-Louis, MO) (1/500). The anti-embryonic Myosin Heavy chain (F1.652, hybridoma supernatant, 1/100) is from the Developmental Studies Hybridoma Bank (DSHB, University of Iowa). Alexa Fluor 488 anti-mouse CD31 (1/500) is from Biologend.

**FACS analysis.** Primary myoblasts were detached at different times of differentiation using a non-enzymic solution, washed and stained with saturating concentrations of primary monoclonal antibody. After washing three times with PBS containing 0.2% BSA, they were incubated with 10  $\mu$ g ml<sup>-1</sup> fluorescein isothiocyanate-labelled secondary antibody. After washing, cells were fixed with 1% formaldehyde in PBS. All incubations were performed for 30 min at 4 °C. Analysis of cell surface staining was performed using a FACSCAN flow cytometer (BD Biosciences).

**Immunofluorescence microscopy and immunohistochemistry.** Primary myoblasts were plated on coverslips coated with collagen and induced to differentiate. They were gently rinsed in PBS and fixed for 15 min in 4% paraformaldehyde/PBS at room temperature. The fixed cells were treated for 10 min with 50 mM NH<sub>4</sub>Cl in PBS, washed in PBS and incubated in PBS containing 2% BSA and 10% heat-inactivated goat serum (blocking buffer, BB). Cells were incubated 1 h with the primary antibody diluted in BB, washed three times in BB and incubated with the corresponding secondary anti-rabbit and anti-rat antibodies conjugated to Alexa 488 or Alexa 568 (Molecular Probes/Invitrogen) diluted in BB for 45 min. Coverslips were washed twice with BB and in PBS and then mounted in Mowiol/DABCO (1,4-diazabicyclo[2.2.2]octane) medium. For immunohistochemistry, serial sections of frozen mouse muscle were fixed for 20 min in acetone at -20 °C, dried and stained as above. Actin was labelled by 5  $\mu$ g ml<sup>-1</sup> of phalloidin tetramethylrhodamine isothiocyanate (Sigma-Aldrich) for 15 min. All immunofluorescent stainings were examined with a Leica DMR fluorescence microscope or a TCS SP5 confocal microscope (Leica, Wetzlar, Germany). To produce three-dimensional projection images we captured frames every 0.13  $\mu$ m to create the z-axis series, which were then combined and processed using the ImageJ software.

**Immunoprecipitation and western blot.** For direct western blot, cells were lysed at 4 °C in RIPA lysis buffer containing 10 mM Tris, pH 7.4, 150 mM NaCl, 0.02% NaN<sub>3</sub>, protease inhibitors, and 1% NP-40, 0.5% deoxycholic acid and 0.1% SDS. Cell extracts were centrifuged at 10,000 r.p.m. for 15 min. For immunoprecipitations, myoblasts were surface labelled or not with EZ-link-Sulfo-NHS-LC-biotin (Pierce, Rockford, IL, USA) as described previously before lysis in 1% Brij97 at 4 °C and immunoprecipitations using Protein G-Sepharose beads (Amersham Biosciences, Rainham, Essex, UK), as previously described<sup>19,20</sup>. After protein separation by SDS-PAGE and transfer to a nitrocellulose membrane, the membranes were incubated with indicated primary antibody and the expression of each protein was revealed with appropriate secondary antibodies labelled with Alexa Fluor 680 (Invitrogen) or IrDye800 (LI-COR). Biotin-labelled surface proteins were revealed using Alexa Fluor 800-labelled streptavidin (Invitrogen). The data were acquired using the Odyssey Infrared Imaging System (LI-COR Biosciences).

**Statistical analysis.** All statistical analyses were performed using the Mann-Whitney test.

## References

- Charge, S. B. & Rudnicki, M. A. Cellular and molecular regulation of muscle regeneration. *Physiol. Rev.* **84**, 209–238 (2004).
- Collins, C. A. *et al.* Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. *Cell* **122**, 289–301 (2005).
- Hawke, T. J. & Garry, D. J. Myogenic satellite cells: physiology to molecular biology. *J. Appl. Physiol.* **91**, 534–551 (2001).
- Abmayr, S. M. & Pavlath, G. K. Myoblast fusion: lessons from flies and mice. *Development* **139**, 641–656 (2012).
- Rochlin, K., Yu, S., Roy, S. & Baylies, M. K. Myoblast fusion: when it takes more to make one. *Dev. Biol.* **341**, 66–83 (2010).
- Doherty, K. R. *et al.* Normal myoblast fusion requires myoferlin. *Development* **132**, 5565–5575 (2005).
- Jansen, K. M. & Pavlath, G. K. Mannose receptor regulates myoblast motility and muscle growth. *J. Cell Biol.* **174**, 403–413 (2006).
- Quach, N. L., Biressi, S., Reichardt, L. F., Keller, C. & Rando, T. A. Focal adhesion kinase signaling regulates the expression of caveolin 3 and beta1 integrin, genes essential for normal myoblast fusion. *Mol. Biol. Cell* **20**, 3422–3435 (2009).
- Madaro, L. *et al.* PKC $\theta$  signaling is required for myoblast fusion by regulating the expression of caveolin-3 and beta1D integrin upstream focal adhesion kinase. *Mol. Biol. Cell* **22**, 1409–1419 (2011).
- Shinn-Thomas, J. H. & Mohler, W. A. New insights into the mechanisms and roles of cell-cell fusion. *Int. Rev. Cell Mol. Biol.* **289**, 149–209 (2011).
- Duelli, D. & Lazebnik, Y. Cell-to-cell fusion as a link between viruses and cancer. *Nat. Rev. Cancer* **7**, 968–976 (2007).
- Le Naour, F., Rubinstein, E., Jasmin, C., Prenant, M. & Boucheix, C. Severely reduced female fertility in CD9-deficient mice. *Science* **287**, 319–321 (2000).
- Rubinstein, E. *et al.* Reduced fertility of female mice lacking CD81. *Dev. Biol.* **290**, 351–358 (2006).
- Martin, F. *et al.* Tetraspanins in viral infections: a fundamental role in viral biology? *J. Virol.* **79**, 10839–10851 (2005).
- Takeda, Y. *et al.* Tetraspanins CD9 and CD81 function to prevent the fusion of mononuclear phagocytes. *J. Cell Biol.* **161**, 945–956 (2003).
- Charrin, S. *et al.* Lateral organization of membrane proteins: tetraspanins spin their web. *Biochem. J.* **420**, 133–154 (2009).
- Yanez-Mo, M., Barreiro, O., Gordon-Alonso, M., Sala-Valdes, M. & Sanchez-Madrid, F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. *Trends Cell Biol.* **19**, 434–446 (2009).
- Hemler, M. E. Tetraspanin functions and associated microdomains. *Nat. Rev. Mol. Cell Biol.* **6**, 801–811 (2005).
- Charrin, S. *et al.* The major CD9 and CD81 molecular partner: Identification and characterization of the complexes. *J. Biol. Chem.* **276**, 14329–14337 (2001).
- Charrin, S. *et al.* EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells. *Biochem. J.* **373**, 409–421 (2003).
- Stipp, C. S., Kolesnikova, T. V. & Hemler, M. E. EWI-2 Is a Major CD9 and CD81 Partner and Member of a Novel Ig Protein Subfamily. *J. Biol. Chem.* **276**, 40545–40554 (2001).
- Stipp, C. S., Orlicky, D. & Hemler, M. E. FPRP, a major, highly stoichiometric, highly specific CD81- and CD9-associated protein. *J. Biol. Chem.* **276**, 4853–4862 (2001).
- Kolesnikova, T. V. *et al.* EWI-2 modulates lymphocyte integrin  $\alpha 4 \beta 1$  functions. *Blood* **103**, 3013–3019 (2003).
- Stipp, C. S., Kolesnikova, T. V. & Hemler, M. E. EWI-2 regulates  $\alpha 3 \beta 1$  integrin-dependent cell functions on laminin-5. *J. Cell Biol.* **163**, 1167–1177 (2003).
- Charrin, S. *et al.* The Ig domain protein CD9P-1 down-regulates CD81 ability to support *Plasmodium yoelii* infection. *J. Biol. Chem.* **284**, 31572–31578 (2009).
- Rocha-Perugini, V. *et al.* The CD81 partner EWI-2 inhibits hepatitis C virus entry. *PLoS ONE* **3**, e1866 (2008).
- Tachibana, I. & Hemler, M. E. Role of transmembrane 4 superfamily (TM4SF) proteins CD9 and CD81 in muscle cell fusion and myotube maintenance. *J. Cell Biol.* **146**, 893–904 (1999).
- Sambasivan, R. *et al.* Distinct regulatory cascades govern extraocular and pharyngeal arch muscle progenitor cell fates. *Dev. Cell* **16**, 810–821 (2009).
- Ferrari, G., Stormaiuolo, A. & Mavilio, F. Failure to correct murine muscular dystrophy. *Nature* **411**, 1014–1015 (2001).
- Gautel, M. The sarcomeric cytoskeleton: who picks up the strain? *Curr. Opin. Cell Biol.* **23**, 39–46 (2011).
- O'Connor, R. S., Steeds, C. M., Wiseman, R. W. & Pavlath, G. K. Phosphocreatine as an energy source for actin cytoskeletal rearrangements during myoblast fusion. *J. Physiol.* **586**, 2841–2853 (2008).
- Nowak, S. J., Nahirney, P. C., Hadjantonakis, A. K. & Baylies, M. K. Nap1-mediated actin remodeling is essential for mammalian myoblast fusion. *J. Cell Sci.* **122**, 3282–3293 (2009).

33. Robertson, T. A., Grounds, M. D., Mitchell, C. A. & Papadimitriou, J. M. Fusion between myogenic cells in vivo: an ultrastructural study in regenerating murine skeletal muscle. *J. Struct. Biol.* **105**, 170–182 (1990).
34. Schroder, J. M. & Adams, R. D. The ultrastructural morphology of the muscle fiber in myotonic dystrophy. *Acta Neuropathol.* **10**, 218–241 (1968).
35. Schotland, D. L., Spiro, D. & Carmel, P. Ultrastructural studies of ring fibers in human muscle disease. *J. Neuropathol. Exp. Neurol.* **25**, 431–442 (1966).
36. Orlicky, D. J. & Nordeen, S. K. Cloning, sequencing and proposed structure for a prostaglandin F2 alpha receptor regulatory protein. *Prostaglandins Leukot. Essent. Fatty Acids* **55**, 261–268 (1996).
37. Orlicky, D. J. Negative regulatory activity of a prostaglandin F2 alpha receptor associated protein (FPRP). *Prostaglandins Leukot. Essent. Fatty Acids* **54**, 247–259 (1996).
38. Horsley, V. & Pavlath, G. K. Prostaglandin F2(alpha) stimulates growth of skeletal muscle cells via an NFATC2-dependent pathway. *J. Cell Biol.* **161**, 111–118 (2003).
39. Park, I. H. & Chen, J. Mammalian target of rapamycin (mTOR) signaling is required for a late-stage fusion process during skeletal myotube maturation. *J. Biol. Chem.* **280**, 32009–32017 (2005).
40. Wakabayashi, T. *et al.* Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains. *Nat. Cell Biol.* **11**, 1340–1346 (2009).
41. Vasyutina, E., Lenhard, D. C. & Birchmeier, C. Notch function in myogenesis. *Cell Cycle* **6**, 1451–1454 (2007).
42. Kopan, R. & Ilgan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. *Cell* **137**, 216–233 (2009).
43. Kitzmann, M. *et al.* Inhibition of Notch signaling induces myotube hypertrophy by recruiting a subpopulation of reserve cells. *J. Cell Physiol.* **208**, 538–548 (2006).
44. Mourikis, P. *et al.* A critical requirement for notch signaling in maintenance of the quiescent skeletal muscle stem cell state. *Stem Cells* **30**, 243–252 (2012).
45. He, Z. Y., Gupta, S., Myles, D. & Primakoff, P. Loss of surface EWI-2 on CD9 null oocytes. *Mol. Reprod. Dev.* **76**, 629–636 (2009).
46. Inoue, N., Nishikawa, T., Ikawa, M. & Okabe, M. Tetraspanin-interacting protein IGSF8 is dispensable for mouse fertility. *Fertil. Steril.* **98**, 465–470 (2012).
47. European Commission. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Pages L276/233–279, Official Journal of European Union (2010).
48. Maecker, H. T. & Levy, S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. *J. Exp. Med.* **185**, 1505–1510 (1997).
49. Rando, T. A. & Blau, H. M. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. *J. Cell Biol.* **125**, 1275–1287 (1994).
50. Silvie, O. *et al.* Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species. *Cell Microbiol.* **8**, 1134–1146 (2006).

## Acknowledgements

We thank Dr S. Levy for the gift of CD81 null mice and Dr S. Tajbakhsh for Tg:Pax7-nGFP mice. S.C. has been supported by fellowships from the Association Française contre les Myopathies (AFM), the Agence Nationale de Recherche (ANR) and Institut du Cancer et d'Immunogénétique (ICIG). M.L. is supported by fellowship awarded by the French government. This work was supported by grants from the ANR, by the associations NRB-Vaincre le Cancer and ICIG.

## Author contributions

S.C. designed the project and experiments, carried out experiments, analysed data and wrote the article. M.L. carried out *in vivo* experiments, analysed data and contributed in writing the manuscript. S.S. performed experiments. A.P. contributed with expertise and reagents. F.C. contributed with expertise, reagents and in writing the article. C.B. contributed with expertise and provided key reagents. E.R. designed the project, analysed data and wrote the article.

## Additional information


**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission information** is available online at <http://npg.nature.com/reprintsandpermissions/>


**How to cite this article:** Charrin, S. *et al.* Normal muscle regeneration requires tight control of muscle cell fusion by tetraspanins CD9 and CD81. *Nat. Commun.* **4**:1674 doi: 10.1038/ncomms2675 (2013).

## Supplementary Figure S1: Expression of CD9 and CD81 in normal adult skeletal muscle




**(a-b)** Cryosections of mouse TA were immunostained as indicated and analyzed by fluorescence microscopy. **(a)** Expression of CD9 (red) and Laminin (LM) (green). **(b)** Colabelling of CD31, an endothelial cell marker (green), with CD9 or CD81 (red). Arrow head indicates a weak staining of CD81 on muscle fiber. **(c,d)** CD9 and CD81 expression on *Tg:Pax7-nGFP* positive cells (satellite cells). Scale bars: 50 μm.

**Supplementary Figure S2: Expression of CD9 and CD81 in regenerating adult skeletal muscle**




(a) Cryosection of mouse TA 4 day post notexin injection stained with an anti-CD9 (red) and an anti-laminin (LM, green) antibodies and analyzed by fluorescence microscopy. (b) Cryosection of mouse TA 12 day post notexin injection stained with anti-CD9 (red) and anti-laminin (LM, green) antibodies and analyzed by confocal fluorescence microscopy. Higher magnification is shown in right panel. (c) One month post injury CD81 staining of myofibers is strongly reduced. (d/e) Cryosections of 6 month old Mdx mouse TA stained with an anti-laminin (LM, green) and anti-CD81 (red) antibodies and analyzed by fluorescence microscopy (d) or an anti-embryonic Myosin Heavy Chain (eMyHC, green) and anti-CD9 (red) antibodies and analyzed by confocal fluorescence microscopy (e). The scale bar in all images is 50  $\mu\text{m}$ .

**Supplementary Figure S3: Expression of CD9P-1 in normal and regenerating adult skeletal muscle.**



Cryosections of mouse Tibialis Anterior (TA) were stained with antibodies to CD9P-1 (red) and either CD31 or CD81 (green), as indicated and analyzed by confocal microscopy. **(a)** Expression of CD9P-1 in normal uninjured muscle; **(b)** Twelve days post notexin injection CD9P-1 is up-regulated in muscle cells and colocalized with CD81. Scale bar: 50  $\mu$ m


**Supplementary Figure S4: Analysis of CD9P-1 function in the fusion of primary myoblasts *in vitro***



**Suppl. Fig. S4: Analysis of CD9P-1 function in the fusion of primary myoblasts *in vitro***

(a) The efficiency of CD9P-1 silencing was determined by western-blot. Silencing yields ~85% inhibition of the expression level of CD9P-1. Under these conditions total CD9 and CD81 expression levels are unchanged. (b) Flow cytometry analysis of CD9 and CD81 expression according to CD9P-1 expression. The histogram shows the mean of two independent experiments +/- SD. (c) Primary myoblasts were transfected with a second siRNA oligonucleotide targeting CD9P-1 (siCD9P-1\_2) or with a control siRNA (siCont). Five fields of each condition were photographed at 10x magnification and nuclei were counted. The histogram shows the mean +/-SD of the percentage of nuclei in cells with different numbers of nuclei and is representative of two different experiments. Ø: not observed. (d) Control (siCont) or CD9P-1-silenced primary myoblasts were induced to differentiate in the presence of vehicle or  $10^{-6}$  M AL-8810, a PGF2 $\alpha$  receptor inhibitor. (e) Primary myoblasts silenced for CD9P-1 were induced to differentiate in the presence of vehicle or 50nM rapamycin, an inhibitor of the mTOR pathway. For **c**, **d** and **e**, the cells were fixed after 48h of differentiation and stained with MGG. Ten fields of each condition were photographed at 10x magnification and nuclei were counted. The histograms show the mean +/-SD of the percentage of nuclei in cells with different numbers of nuclei and are representative of at least two different experiments. Ø: not observed. (f) Quantification of myotubes diameters after rapamycin treatment. Five fields of each condition were photographed at 10x magnification and the diameters of myotubes were measured. The histogram shows the mean +/-SD of the diameters and is representative of two different experiments. (g) Quantification of Notch target genes Hes-1 and Hey-1 activation by QRT-PCR expressed in percentage of the control according to CD9P-1 expression. The histogram shows the mean of three independent experiments +/- SD. (\*\* $p < 0.01$  as compared to control).

**Supplementary Figure S5: Alpha-actinin organization is abnormal in giant dystrophic myofibers during regeneration - Other examples**



Confocal immunofluorescent images: 3D projection of a z series of cryosections of TA from mutant mice stained with Dapi (blue), an anti-laminin antibody (red) and an anti-actinin (gray). Yellow symbols (\* ♦) show various patterns of  $\alpha$ -actinin in one dystrophic myofiber, arrows show internal laminin (**a/b**: CD9<sup>-/-</sup>; **c/d**: CD81<sup>-/-</sup>). Different magnifications are shown, Scale bar: 20 $\mu$ m.